By LabPulse.com staff writers

June 20, 2019 -- McKesson is now a nonexclusive distributor of Qiagen's QIAstat-Dx syndromic system for respiratory and gastrointestinal diseases in smaller U.S. hospitals, and it is also managing sales in nonacute retail pharmacies.

The QIAstat-Dx respiratory panel for detecting more than 20 respiratory viral and bacterial pathogens was cleared by the U.S. Food and Drug Administration (FDA) in May for use with the QIAstat-Dx syndromic testing system.

McKesson and Qiagen are targeting smaller facilities. There are approximately 2,000 hospitals in the U.S. with 200 or fewer beds, accounting for about 10% of the total market for syndromic testing nationally and $650 million in annual sales, according to the companies.

Qiagen and DiaSorin heed call for better Lyme disease test
Qiagen and DiaSorin are teaming up on the development of a more sensitive test to enable earlier detection of Lyme disease, with plans in 2020 to validate...
Qiagen launches newly cleared PIK3CA test pronto
Qiagen is immediately launching its therascreen test kit for mutations of the PIK3CA gene, following clearance on May 24 by the U.S. Food and Drug Administration...
Qiagen liquid biopsy to guide Inovio immunotherapy
Qiagen is developing a liquid biopsy companion diagnostic for Inovio's investigational VGX-3100 immunotherapy for the nonsurgical treatment of advanced...

Copyright © 2019 LabPulse.com



Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Email